Meenal Kheterpal is a Dermatology physician affiliated with Duke Medical Center. OpenAlex indexes 80 publications with 836 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9650 Strickland Rd Ste 103-279
Raleigh, NC 276151902
Telephone
501-232-1001Provider last certified this registry record 30 Dec 2025.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202518 payments$40,663openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202524 payments$38,625openpaymentsdata.cms.gov ↗
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202445 payments$56,539openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
24%Hedgehog Pathway Inhibitor5.2%Odomzo100%Part D<11 patientsPhosphodiesterase 4 Inhibitor5.2%Otezla100%Part D<11 patients+ 3 more classes in this area
Sensory organs
23.3%Corticosteroid23.3%Clobetasol Propionate50%Betamethasone Diprop Augmented38%Hydrocortisone12%Part D<11 patientsDermatology
18.6%Corticosteroid8.5%Triamcinolone Acetonide100%Part D≥25 patientsRetinoid6.8%Acitretin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 5-aminolevulinic acid photodynamic therapy for the treatment of basal and squamous cell carcinoma: A systematic review
Photodiagnosis and Photodynamic Therapy
2025 - Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
2025 - Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndrome
Journal of the American Academy of Dermatology
2025 - Management of human epidermal growth factor receptor inhibitors‐related acneiform rash: A position paper based on the first Europe/<scp>USA</scp> Delphi consensus process
Journal of the European Academy of Dermatology and Venereology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
James Abbruzzese, MD
Duke Medical Center
David Durack, MD
Duke Medical Center
Leonard Prosnitz, MD
Duke Medical Center
Scott Cousins, MD
Duke Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”